Filgrastim in Patients with Neutropenia: Potential Effects on Quality of Life

Lyman, G.H.; Kuderer, N.M.
June 2002
Drugs;2002 Supplement 1, Vol. 62 Issue 9, p65
Academic Journal
Treatment- and disease-related neutropenia are associated with a number of negative clinical effects such as febrile neutropenia, documented infection, hospitalisation for infection-related morbidity, infection-related mortality, and decreased ability to administer the planned chemotherapy dose on schedule. Reductions or delays in dosage have the ability to jeopardise the effectiveness of treatment by lowering response rates. Not only are clinical outcomes adversely affected, but these complications can have a negative influence on patient quality of life. Filgrastim is a haematopoietic growth factor that primarily acts to stimulate the proliferation and differentiation of neutrophil progenitor cells. Filgrastim is capable of reducing the incidence and severity of neutropenia and the complications that accompany it in patients with cancer or HIV infection. Although there are few data evaluating the effect of treatment with granulocyte colony-stimulating factor on quality of life, it is assumed that the benefits would be seen through both the reduction of treatment-related complications and the enhanced potential for long-term disease control. A new, longer-acting form of filgrastim is now available that has the potential to simplify the management of neutropenia and further improve patient quality of life by decreasing the number of necessary injections. Additional prospective controlled trials that contain quality-of-life issues as endpoints are needed .


Related Articles

  • Filgrastim.  // Reactions Weekly;8/3/2013, Issue 1464, p22 

    The article presents a case study about the development of tumour lysis-like syndrome in a 61-year-old man after receiving filgrastim for febrile neutropenia.

  • Filgrastim and Pegfilgrastim Use in Patients With Neutropeni. Quirion, Eva // Clinical Journal of Oncology Nursing;Jun2009, Vol. 13 Issue 3, p324 

    Myelosuppression, the reduction of platelets and red and white blood cells, is the most common side effect of chemotherapy. Filgrastim and pegfilgrastim are used to assist recovery in patients with low white blood cell counts. This article explores the dosing, efficacy, cost, and clinical...

  • Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®. Crobu, Davide; Spinetti, Gaia; Schrepfer, Rodolfo; Tonon, Giancarlo; Jotti, Gloria Saccani; Onali, Pierluigi; Dedoni, Simona; Orsini, Gaetano; Di Stefano, Andrea // BMC Pharmacology & Toxicology;2014, Vol. 15 Issue 1, p1 

    Background: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with nonmyeloid malignancies. In addition to its role in the regulation of...

  • Filgrastim.  // Reactions Weekly;12/8/2012, Issue 1431, p20 

    The article describes the case of a 53-year-old woman who experienced Sweet's syndrome during treatment with filgrastim.

  • Filgrastim.  // Reactions Weekly;11/17/2012, Issue 1428, p18 

    The article describes the case of a 62-year-old man who developed bone marrow necrosis during filgrastim therapy for stage IA Burkitt's lymphoma.

  • Filgrastim/methotrexate.  // Reactions Weekly;1/19/2013, Issue 1435, p13 

    The article describes the case of a 51-year-old woman suffering from rheumatoid arthritis who developed neutropenia while receiving methotrexate and subsequently developed acute respiratory distress syndrome (ARDS) unmasking pneumocytis pneumonia (PCP) during treatment with filgrastim.

  • Lenograstim.  // Reactions Weekly;4/28/2012, Issue 1399, p20 

    The article describes the case of a 36-year old man who developed pulmonary micro-embolism after he was treated with lenograstim.

  • Filgrastim.  // Reactions Weekly;Nov2014, Vol. 1528 Issue 1, p94 

    The article presents a case study of a 54-year-old woman who developed Sweet's syndrome following administration of filgrastim.

  • Antineoplastics/filgrastim.  // Reactions Weekly;11/5/2011, Issue 1376, p8 

    The article describes the case of a male patient who developed hypertrichosis of the ears while undergoing antineoplastic and filgrastim therapy for testicular cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics